Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 1/20 | 0.36 |
| ▸ | PGK2 | P07205 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | ACP3 | P15309 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2154816 | 0.77 | OPRM1 (0.47) | PGK1PGK2DRD4OPRM1DRD3 | |
| SCHEMBL1451743 | 0.74 | PIN1 (0.43) | TSHRSMN1; SMN2NPC1KMT2AMEN1 | |
| SCHEMBL3884603 | 0.71 | PGK1 (0.42) | PGK1PGK2TSHRACHEPTPN1 | |
| SCHEMBL2155108 | 0.69 | HPGD (0.37) | HPGDSMN1; SMN2KMT2APOLB | |
| O-Xylene SCHEMBL1502379 | 0.69 | TSHR (0.62) | PGK1PGK2TSHRACHEHPGD | |
| O-Xylene SCHEMBL29061119 | 0.69 | TSHR (0.62) | PGK1PGK2TSHRACHEHPGD | |
| O-Xylene SCHEMBL29498826 | 0.69 | TSHR (0.62) | PGK1PGK2TSHRACHEHPGD | |
| O-Xylene SCHEMBL30374736 | 0.69 | TSHR (0.62) | PGK1PGK2TSHRACHEHPGD | |
| O-Xylene SCHEMBL17255245 | 0.69 | TSHR (0.62) | PGK1PGK2TSHRACHEHPGD | |
| O-Xylene SCHEMBL30445238 | 0.69 | TSHR (0.62) | PGK1PGK2TSHRACHEHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2519100-B1 | INTERMEDIATE COMPOUNDS AND PROCESSES FOR THE PREPARATION OF TAPENTADOL AND RELATED COMPOUNDS | MAPI PHARMA LTD (IL) | 2017-03-15 | — | — | EP | disclosed |
| US-8410176-B2 | Intermediate compounds and processes for the preparation of tapentadol and related compounds | MAPI PHARMA LTD. (IL) | 2013-04-02 | — | — | US | disclosed |
| US-20120283463-A1 | INTERMEDIATE COMPOUNDS AND PROCESSES FOR THE PREPARATION OF TAPENTADOL AND RELATED COMPOUNDS | MAPI PHARMA LIMITED (IL) | 2012-11-08 | — | — | US | disclosed |
| EP-2519100-A1 | INTERMEDIATE COMPOUNDS AND PROCESSES FOR THE PREPARATION OF TAPENTADOL AND RELATED COMPOUNDS | Mapi Pharma Limited (IL) | 2012-11-07 | — | — | EP | disclosed |
| WO-2011080736-A1 | INTERMEDIATE COMPOUNDS AND PROCESSES FOR THE PREPARATION OF TAPENTADOL AND RELATED COMPOUNDS | MAPI PHARMA HK LIMITED (CN) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283463-A1 | INTERMEDIATE COMPOUNDS AND PROCESSES FOR THE PREPARATION OF TAPENTADOL AND RELATED COMPOUNDS | PNMT, OPRK1, CYP2E1 | PGK1 1557/4885PGK2 1656/4885DRD4 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.